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INTRODUCTION • Timetoconfirmeddisabilityprogression,measuredbytheExpandedDisabilityStatusScale(EDSS),
is a key regulatory endpoint in pivotal relapsing-remitting multiple sclerosis (RRMS) trials.
• Although the EDSS has widely discussed limitations, including inter-and intra-rater variability, lack of sensitivity, poor responsiveness, inconsistent reliability, non-linearity, and poor incorporation of cognitive impairment symptoms, it remains the regulatory standard and precedent for demonstrating the effect of a therapy on delaying disability progression in RRMS.
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• Severalapprovedtherapieshaveshownresultsthatareinconsistentintermsofstatisticalsignificance on this endpoint when evaluated in 2 pivotal RRMS trials for superiority versus the same comparator.
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• Theestimatedeffectsofagiventherapyonthisendpointacrosstrialsmaybeinfluencedbyvarious factors, including differences in study designs, baseline characteristics of the enrolled populations, andendpointdefinitions. 10 
OBJECTIVE
• Tofurtherunderstandfactorspotentiallyinfluencingresultsforthetimeto12-weekconfirmed disability progression endpoint in the 2 phase 3 studies of delayed-release dimethyl fumarate (DMF; alsoknownasgastro-resistantDMF),DEFINEandCONFIRM,bycontextualizingdifferencesinthe endpoint's results. • Disabilityprogressionrequiredconfirmationintheabsenceofaconfirmedrelapse.Apatientwas consideredtohaveaconfirmedrelapsefor29daysafterthestartdateofaconfirmedrelapse.Ifa patientmetthecriteriafor12-weekconfirmedprogressioninthepresenceofaconfirmedrelapse,the patientwasrequiredtohavetherequisiteincreasefrombaselineinEDSSatthesubsequentvisit.
METHODS
• Timeto12-weekconfirmeddisabilityprogressionat2yearswasthefourthsecondaryendpointin bothstudies.Secondaryendpointswererankprioritized,withaclosedtestingprocedureusedto control for the type I error rate due to multiplicity, which included both the ranking of the secondary endpoints and the comparison of each dose group with placebo. However, the studies were not powered for this endpoint.
• To address potential ethical concerns associated with using placebo as a comparator at a time when effective MS therapies were available, patients had the option of discontinuing study treatment and initiating alternative (rescue) MS therapy at any time during the studies due to 12-weekconfirmeddisabilityprogressionoraftercompleting48weeksofstudytreatmentand experiencing1confirmedrelapseafter24weeks(DEFINE)or2confirmedrelapsesatanytime (CONFIRM). Relapse-based criteria for alternative therapy were designed to allow for appropriate ascertainment of the different primary endpoints of the 2 studies (DEFINE: proportion of patients relapsed at 2 years; CONFIRM: annualised relapse rate at 2 years).
Statistical Analysis Methodology
• Thetreatmenteffectfortimeto12-weekconfirmeddisabilityprogressionforeachDMFgroup relativetoplacebowasestimatedusingaCoxproportionalhazardsmodel,adjustedfortreatment, baselineEDSSvalue(asacontinuousvariable),region,andage(<40vs≥40).Theproportionsof patientswith12-weekconfirmeddisabilityprogressionineachtreatmentgroupwereestimated using the Kaplan-Meier product limit method.
• Theprimaryanalysisoftimeto12-weekconfirmeddisabilityprogressionexcludedprogressionwith onset after initiation of alternative therapy, with patients censored at the last EDSS assessment priortoinitiatingalternativetherapyiftheyhadnotexperiencedprogression.However,EDSS evaluationsperformedafteralternativetherapywasinitiatedcouldbeusedtoconfirmtentative progressionexperiencedpriortoinitiationofalternativetherapy.Additionally,ifapatienthad tentativeprogressionatthefinalEDSSassessmentatWeek96,thefirstEDSSassessmentat Week12oftheextensionstudy 6,7
wasusedforconfirmation.
• To evaluate potential informative censoring, post hoc sensitivity analyses were performed to assess the effect of switch to alternative therapy and study withdrawal, as well as other potential factors, on the endpoint.
• Apooledanalysisof12-weekconfirmeddisabilityprogressionwaspre-specifiedpriorto unblinding of CONFIRM and performed using integrated data from both studies. Accepted purposes for meta-analysis according to regulatory guidance 11 and applicable in this situation includeobtainingmorepreciseestimatesofoveralltreatmenteffect,evaluatinganefficacy outcomethatrequiresmorepowerthantheindividualstudiescanprovide,andevaluatingand puttingintoperspectiveapparentlyconflictingstudyresults. -The pooled analysis was performed with consideration given to the consistency in study designs,baselinecharacteristics,andtreatmenteffectsfor12-weekconfirmeddisability progression (both overall and in relevant baseline subgroups) across the studies, using a stratifiedCoxproportionalhazardsmodelwithstudyasthestratificationfactor,adjustingfor thesamecovariatesasintheindividualstudyanalyses.StratificationoftheCoxmodelfor pooled analysis on the factor of study had the advantage of allowing the form of the baseline hazardfunctiontovaryacrossthestudieswithoutrequiringestimatingtheeffectofstudy orrequiringstudytosatisfytheproportionalhazardsassumption.Thisappearedtobea reasonable model given the individual study results.
• Analyses presented here include results for placebo and the DMF 240 mg BID group, as this is the approved dosing regimen; results for the DMF 240 mg TID group (not shown) were similar to those of the BID dose group.
RESULTS
• Studies were generally similar in terms of patient baseline demographic and disease characteristics (Table 1 ).
• • Treatment effects were considered to be consistent, based on a critical evaluation of heterogeneity in accordance with regulatory guidance.
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This included assessment of consistency of treatment effect across studies performed descriptively and graphically (Figure 3, primary analyses) , as well asbystatisticaltestingofthestudy-by-treatmentinteraction(P=0.7182),resultinginaconclusion of lack of heterogeneity.
• Therewasanapparentdifferenceintheestimatedproportionwith12-weekconfirmeddisability progressionintheplacebogroupat2yearsinCONFIRM(16.9%),ascomparedtothealmost concurrentlyenrolledDEFINE(27.1%),potentiallycontributingtodecreasedassaysensitivity andlackofstatisticalsignificanceinCONFIRM.
• In both studies, a relatively higher percentage of placebo patients compared with DMF 240 mg BID-treated patients switched to alternative therapy or withdrew from study after the time of tentativedisabilityprogressionwithoutasubsequentEDSSassessment,therebynotaffordingthe opportunitytoconfirm12-weekdisabilityprogression(Table2),particularlycontributingtoalower placebo progression rate in CONFIRM.
• Since relapse-based criteria for switching to alternative therapy differed between the 2 studies, relapseandprogressionstatuswerefurtherexaminedinpatientswhoswitched:amongplacebo patients who switched, relapse activity prior to switch differed in the studies: a relatively higher percentageofplacebopatientswhoswitchedhad≥2relapseswithout12-weekconfirmeddisability progressionpriortoswitchinCONFIRM(45%)comparedwithDEFINE(16%),asmaybeexpected based on the differences between studies in relapsed-based criteria for switching (Figure 2 ).
• Thefollowingadditionalexploratoryanalyseswereconductedtoassessotherpotentialreasonsforthe apparent differences between studies in treatment effects and 2-year placebo rates for disability progression: -Amount of missing EDSS data in both studies -Rate and pattern of study drug discontinuation overall and by treatment group -Baseline demographic and disease characteristics in patients who discontinued study drug and who withdrew from study -ConsistencyoftheexaminingneurologistperformingEDSSassessmentsforagivenpatient at a given site -Impact of regional enrollment and prior MS medication use in the studies on estimated treatment effects • None of these evaluations revealed clear differences between the studies and therefore did not appeartoofferpotentialexplanationsforapparentstudydifferences.
• • Sincethesepatientswith≥2relapsesareknowntobeatgreaterriskofprogression 12,13 and were censored in the primary analysis at the last EDSS assessment prior to switch, it is possible theycontributedtothelowplaceboprogressionrateat2yearsandlackofstatisticalsignificance in CONFRIM.
• To further evaluate this effect of switch to alternative therapy, 2 sets of sensitivity analyses were performed in each study: (1) switch to alternative therapy was considered as progression for all patients who switched; and (2) switch to alternative therapy was considered as progression only forthosepatientswhoswitchedhavinghad2ormorerelapseswithout12-weekconfirmed disability progression.
• These sensitivity analyses demonstrated compelling treatment effects, with HRs ranging from 0.57 to0.76,representingrelativereductionsof24%-43%intheriskofprogression(Figure3).
-InDEFINE,bothsensitivityanalysesdemonstratedstatisticalsignificance,whileinCONFIRM, sensitivity analysis 1 considerably reduced the P value (from 0.2536 to 0.1243), and sensitivity analysis2demonstratedstatisticalsignificance. 
